Invloed van corticoïden op de nierfunctie postoperatief na cardiochirurgie

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-005733-35-BE

Enrollment

Registered

2006-02-07

Start date

2007-03-01

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patiënten met cardiale pathologie (klep en/of coronair)

Interventions

Trade Name: Solu-Medrol Product Name: methylprednisolon Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Methylprednisolon CAS Number: 83-43-2 Concentration unit: mg milligr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Leeftijd : 20 – 80 j Geslacht : M/V Patienten met electieve cardiale chirurgie Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: niet electieve chirurgie electief indien - creatinine > 2 mg/dl - behandeling met corticosteroïden ( oraal ) of andere immunosuppressiva

Design outcomes

Primary

Measure	Time frame
Main Objective: De invloed van corticoïden op de nierfunctie postoperatief na cardiochirurgie nagaan.;Secondary Objective: ;Primary end point(s): Daling van de nierfunctie postoperatief na cardiochirurgie is lager bij gebruik van corticoïden versus placebo.	—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026